A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 38/17 (2006.01) A61K 38/20 (2006.01) A61K 39/35 (2006.01)
Patent
CA 2164848
A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of autoimmune diseases such as, for example, multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, autoimmune myocardis, allergic disorders such as hay fever, extrinsic asthma, or insect bite and sting allergies. food and drug allergies, as well as for the treatment or prevention of graft rejection.
L'invention concerne un procédé de traitement ou de prévention de maladies auto-immunes, de troubles allergiques ou atopiques, et de rejets de greffe, consistant à induire la mort par apoptose d'une sous-population de lymphocytes T qui est capable de provoquer ces maladies tout en n'affectant pratiquement pas la majorité des autres lymphocytes T. La mort cellulaire s'effectue par cycles(s) consistant à provoquer par immunisation ces lymphocytes T avec une substance antigénique par intervalles de courte durée, ou par immunisation, puis administration de l'interleukine-2 (IL-2) lorsque ces lymphocytes T expriment des niveaux élevés du récepteur de IL-2 de façon à soumettre ces lymphocytes T à l'apoptose lors de la réimmunisation avec le peptide ou la protéine antigénique. Ces procédés peuvent être appliqués dans le traitement des maladies autoimmunes telles que, par exemple, la sclérose en plaques, l'uvéite, l'arthrite, les diabètes insulinodépendants de type I, la tyroïdite chronique de Hashimoto, la tyroïdite de Grave, la myocardite autoimmune, etc., les troubles allergiques tels que le rhume des foins, l'asthme extrinsèque, ou les allergies aux morsures et piqûres d'insectes, les allergies aux aliments et aux médicaments, ainsi que dans le traitement ou la prévention du rejet de greffe.
Department O. F. Health And Human Services The United States Of America Represented By The Secretary
Fetherstonhaugh & Co.
The United States Of America Represented By The Secretary Department Of
LandOfFree
Interleukin-2 stimulated t lymphocyte cell death for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-2 stimulated t lymphocyte cell death for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-2 stimulated t lymphocyte cell death for the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1981645